



National Institute of
Allergy and
Infectious Diseases

Funding Initiatives and Concepts of Interest to HIV Cure Researchers and Early- Career Investigators

July 16, 2023

NOT-AI-23-046: Notice of Special Interest (NOSI): HIV Cure-Related Research in Diverse Populations (R21, R01)

- **Purpose:** To determine the influence of variables such as virus clade, sex, race, age, co-infections, and comorbidities on HIV reservoir dynamics and post-treatment control
- **Standard AIDS due dates**
- **First Available Due Date:** September 07, 2023
- **Expiration Date:** May 08, 2026
- **Scientific Contacts:** Leia Novak (NIAID), Peter Perrin (NIDDK), Jeymohan Joseph (NIMH)

NOT-AI-22-072: Notice of Special Interest (NOSI): Opportunities for HIV Cure Interventions at the Time of ART Initiation (R21, R01)

- **Purpose:** To identify new opportunities for cure interventions administered during active HIV infection at or near the start of antiretroviral therapy (ART) or as a potential replacement for conventional ART
- **Standard AIDS due dates**
- **Next Available Due Date:** September 07, 2023
- **Expiration Date:** September 08, 2025
- **Scientific Contacts:** Brigitte Sanders/Leia Novak (NIAID), Eric Lorenzo (NICHD), Jeymohan Joseph (NIMH)

RFA-AI-23-018: Defining Mechanisms of HIV Induced Inflammation and Immune Activation During Suppressive Antiretroviral Therapy (ART) (R01)

- **Purpose:** To define the molecular mechanisms by which HIV proteins and/or nucleic acids induce inflammation, immune activation and HIV persistence during viral suppression as well as on developing novel therapeutic strategies to mitigate or eliminate the effects of continued HIV expression
- **Due date:** August 02, 2023
- **Scientific Contact:** Gerard Lacourciere (DAIDS/NIAID)

RFA-AI-23-026: Synthetic Nucleic Acid Platforms for HIV-1 (SNAPH): (R61/R33)

- **Purpose:** To advance synthetic nucleic acid platforms for the rapid development and iterative testing of active and passive immunization strategies for HIV prevention, treatment, and cure
- **Due date:** August 02, 2023
- **Scientific Contacts:** Angela Malaspina, Brigitte Sanders, Stephen Smiley (DAIDS/NIAID)

PAR-22-241: NIAID Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01)

- **Purpose:** To support researchers that are underrepresented in the health-related sciences (as defined in the PAR)
- (*'At-Risk'* is defined as a PI who is in their last year of independent research funding)
- **Standard AIDS due dates**
- **Next Available Due Date:** September 07, 2023
- **Expiration Date:** September 08, 2025
- **Scientific Contact:** Eric Refsland (NIAID/DAIDS)

PAR-23-198: NIAID New Innovators Awards (DP2)

- **Purpose:** To support postdoctoral and other non-independent investigators or newly independent ESIs of exceptional creativity who propose novel, high-impact research to test scientific paradigms or advance key concepts on broad, important problems in biomedical research of priority to NIAID
- Applications proposing unexpected convergence of disciplines, new scientific directions, or the use of novel methodologies are encouraged.
- **Budget:** \$1.5 M Total over 5 years
- **Due Dates:** October 13, 2023; October 11, 2024; October 10, 2025
- **Scientific Contact:** Diane Lawrence (DAIDS/NIAID)

PAR-21-038: Stephen I. Katz Early Stage Investigator Research Project Grant (R01)

- **Purpose:** To support innovative projects that represent a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist.
- No preliminary data allowed.
- Separate attachment required describing the change in research direction
- **Remaining AIDS Due Dates:** August 26, 2023; December 28 2023
- **Scientific Contact:** Madelon Halula (DAIDS/NIAID)

PAR-23-225: HIV/AIDS Scholars Using Nonhuman Primate (NHP) Models Program (K01)

- **Purpose:** To support translational studies by Early-Stage Investigators using NHPs under the guidance of an experienced mentorship team with expertise in both the pre-clinical application of NHP HIV/AIDS models and in translation of the results from such studies to clinical application in humans.
- 3 years of support for intensive research career development
- **Standard AIDS due dates**
- **Next Available Due Date:** September 07, 2023
- **Expiration Date:** September 08, 2025
- **Scientific Contact:** Eric Refsland (DAIDS/NIAID)

PAR-23-073: Mentored Career Development Program for Early Stage Investigators Using Nonhuman Primate Research Models (K01)

- **Purpose:** To support translational studies by Early-Stage Investigators using NHPs under the guidance of an experienced mentorship team with expertise in both the pre-clinical application of NHP HIV/AIDS models and in translation of the results from such studies to clinical application in humans.
- Up to 5 years of support for intensive research career development
- **Standard AIDS due dates**
- **Next Available Due Date:** September 07, 2023
- **Expiration Date:** January 8, 2026
- **Scientific Contact:** Bruce Fuchs (ORIP/NIH)

PAR-22-185: Resources Access for Preclinical Integrated Drug Development (RAPIDD) Program (X01)

- **Purpose:** To provide investigators working on the development of novel therapeutic products for HIV with a mechanism to request NIAID DAIDS preclinical services to fill gaps in their product development efforts and facilitate the advancement of promising therapeutics from bench to clinics
- **AIDS Due Dates:** September 01, 2023; January 17, 2024; September 01, 2024; January 17, 2025
- **Scientific Contacts:**
 - **In Vitro Testing and Screening of HIV compounds** – Betty Poon (DAIDS/NIAID)
 - **Evaluations in Small Animal Models for HIV** – Brigitte Sanders (DAIDS/NIAID)
 - **Formulation Development and Manufacture of Clinical Dosage Forms; Preclinical Pharmacology and Toxicology** – Marina Protopopova (DAIDS/NIAID)

June 2023 DAIDS Council-Approved Concepts for FY 2025

Tailoring HIV Curative Strategies to the Individual

- **Scientific Contact:** Leia Novak (DAIDS/NIAID)

Developing a Pipeline of Cell and Gene Therapies for HIV Cure

- **Scientific Contact:** Betty Poon (DAIDS/NIAID)

Engineering and Preclinical Development of Biological Products that Eliminate HIV-Infected Cells

- **Scientific Contact:** Stephen Smiley, Yan Zhou (DAIDS/NIAID)

<https://www.niaid.nih.gov/grants-contracts/june-2023-daids-council-approved-concepts>

ACTG: Small Clinical Trials Advancing HIV Remission And Cure

- **Purpose:** To provide a pathway to conduct small experimental trials (less than 30 participants; 1-3 sites) that aim to advance efforts related to HIV remission and cure utilizing the ACTG infrastructure and conducted at currently funded core ACTG sites
- **Twice Annual Due Dates:** April; October
- **Next Available Due Date:** October 2, 2023
- **Website:** <https://actgnetwork.org/small-clinical-trials-advancing-hiv-remission-and-cure/>